FLOVID-20
TARGETED T-CELL IMMUNOTHERAPY
A treatment for new COVID-19 patients. Administered by inhaler.
Designed to prevent severe COVID-19 disease and cure COVID ‘long-haulers’.
Under Development. FDA Approval Required.
FLOVID-20
Targeted T-Cell Immunotherapy
Predicted to work against all variants
of COVID-19 Virus
A Growing Mutation Threat
Addresses All Variants
Seeing is Believing
FLOVID-20 showed efficacy in a pre-clinical study in non-human primates, protecting against COVID-19 pneumonia.
FLOVID-20
Targeted T-Cell Immunotherapy
Predicted to work against all variants
of COVID-19 Virus
A Growing Mutation Threat
Addresses All Variants
Seeing is Believing
FLOVID-20 showed efficacy in a pre-clinical study in non-human primates, protecting against COVID-19 pneumonia.
About Strategic Vaccines
A public private partnership created
to commercialize targeted T-Cell Immunotherapy
for treatment and prevention of viral diseases
News
Flow Pharma Announces Publication of Pre-Clinical Efficacy Study for FlowVax COVID-19 Vaccine
Wednesday, May 19, 2021
New Research: Paired SARS-CoV-2 viral transfer from humans to minks and Back to humans
Tuesday, May 11, 2021
Peptide nucleocapsid vaccine candidate elicits protective T cell immunity against SARS-CoV-2 in vivo
Wednesday, April 28, 2021
New FLOVID-20 Research Results in Rhesus Monkeys
Tuesday, April 27, 2021
SARS-CoV-2 Mutations Continue to Rise
Sunday, March 14, 2021
Statement from Lockheed Martin CEO on 2020 COVID-19 Commitment and Impact
Friday, December 11, 2020
Strategic Vaccines, LLC Hires Lockheed Martin
Thursday, November 19, 2020
COVID-19 patients
expect effective treatment.
FLOVID-20 will provide the Efficacy, Safety, and Convenience patients seek.
Efficacy
Designed to eliminate severe disease, hospitalization, death,
and 'long-hauler syndrome'
Safety
Assembled from FDA approved components
Pre-clinical studies show no adverse events
Convenience inhaled, single dose, patient-friendly, simple
Founding companies
Partner companies
Founding companies
Partner companies